Sechenov School
Home › Microbiology › Acinetobacter

Acinetobacter

Acinetobacter

For medical students2 min readUpdated 2026-10-10

Acinetobacter species are Gram-negative bacteria ranking second among hospital-acquired (nosocomial) pathogens. Widely distributed in the environment, they pose a serious threat to immunocompromised patients, causing wound infections, respiratory tract infections, and severe systemic complications.

MorphologyShort Gram-negative bacilli with a tendency toward polymorphism
Main ThreatNosocomial infections (especially A. baumannii)
RespirationStrict aerobes
TreatmentSensitivity to neomycin and polymyxin has been noted

Morphology and Culture Characteristics

The genus Acinetobacter is represented by Gram-negative bacteria. Structurally, they appear as short, relatively thick bacilli measuring 1.5 to 2.5 µm in length. Pronounced polymorphism is characteristic: smears frequently reveal coccoid or ovoid forms. Cells are arranged randomly, in pairs, or in short chains.

These bacteria do not form spores and lack flagella, rendering them non-motile. However, they possess fimbriae and, under certain conditions, can form a protective capsule.

Acinetobacter species are strict aerobes and have minimal nutritional requirements. They grow well on standard nutrient media at 30–35 °C with a neutral pH (approximately 7.0). Colonies appear small and glistening. When cultured on blood agar, some strains may demonstrate a zone of $\beta$-hemolysis.

Their biochemical activity is relatively weak:

Pathogenicity and Epidemiology

In nature, Acinetobacter species are ubiquitous, frequently isolated from soil and water. They can also act as part of the human transient microflora, often found on the skin and nasopharyngeal mucosa of completely healthy individuals.

The pathogenic potential of these microorganisms is mediated by several key virulence factors:

  1. Capsule — provides anti-phagocytic activity, protecting the microbe from immune system attacks.
  2. Adhesins — specialized structures that help bacteria firmly attach to epithelial cells.
  3. Lipopolysaccharide (LPS) of the cell wall — acts as a potent toxic factor upon bacterial lysis.

In clinical practice, the most significant species are A. baumannii (the primary pathogen), A. lwoffii, and A. haemolyticus, while A. calcoaceticus is considered the type species. The highest-risk groups for infection include infants, middle-aged adults, and patients with severe immunodeficiencies.

Clinical Manifestations and Diagnostics

Nosocomial infections caused by Acinetobacter species present a major medical challenge. They securely hold second place in the structure of hospital-acquired infections, second only to Pseudomonas.

Main localizations of the infectious process:

To identify the pathogen, blood, pus, or discharge from infected wounds is collected. Laboratory diagnostics is performed in several stages:

  1. Microscopy (evaluation of morphology and Gram staining).
  2. Culture method (isolation of a pure culture on nutrient media).
  3. Identification of the isolated strain based on its biochemical properties.

Specific vaccines for infection prophylaxis have not yet been developed. In treatment, susceptibility of the pathogens to antibacterial agents such as neomycin and polymyxin has been observed.

Mnemonic

To remember their biochemical inertness, imagine Acinetobacter as "lazy" microbes. They do not want to break down polysaccharides and produce neither indole, nor hydrogen sulfide, nor lysine.

Frequently asked questions

What modern antibiotic groups are used to treat Acinetobacter baumannii infections?

Carbapenems, fluoroquinolones, polymyxin, and neomycin are used to treat Acinetobacter infections. Carbapenems serve as the drugs of choice for empirical therapy of severe infections.

  • Carbapenems — imipenem and meropenem (the activity of meropenem against Acinetobacter is 8–16 times higher).
  • Fluoroquinolones — used in therapy, though fluoroquinolone-resistant strains present a significant challenge.
  • Polymyxin and neomycin — susceptibility of the pathogen to these agents has been reported.

When multidrug-resistant, carbapenem-resistant, or pandrug-resistant Acinetobacter spp. strains are isolated, alternative drugs or combinations of 2–3 antibiotics at maximum tolerated doses are prescribed to overcome resistance mechanisms.

What biological specimens are collected for testing when an Acinetobacter infection is suspected?

When an Acinetobacter infection is suspected, blood, pus, and wound discharge are collected for analysis. Clinical samples for microbiological testing should be obtained prior to the initiation of antimicrobial therapy.

Which Acinetobacter species is most clinically significant?

A. baumannii has the greatest clinical significance, serving as the leading hospital-acquired pathogen within this group.

Are these bacteria motile?

No, Acinetobacter species are non-motile because they lack flagella. However, they possess fimbriae for tissue adhesion.

Are there vaccines against Acinetobacter?

No, specific prophylaxis (vaccination) against these pathogens has not been developed to date.

Go deeper

More topics in Microbiology

Fungal PhysiologyWound Microbiological ExaminationMolecular Hybridization MethodComplications of Antimicrobial ChemotherapyInnate Immune ReceptorsEnterobacteriaceaeGardnerella vaginalisCholera: Clinical Presentation, Diagnosis, and TreatmentSterilization: Methods, Control, and MicrobiologyImmune StatusDiagnosis, Treatment, and Prevention of MycotoxicosesBacterial Nucleoid and PlasmidsMicrobiology →